New Prostate Cancer Test Ready for General Use
Health Discovery Corporation (HDC) announced Aug. 11 that its new gene-based molecular diagnostic test for prostate cancer has now successfully completed its phase III double-blind clinical trial. According to a Medical News Today report, the test is now ready for commercialization to be used by physicians on their patients at risk of having prostate cancer.
Latest posts by admin aapc (see all)
- US gets the ball rolling on ICD-11 - August 16, 2019
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018